Overall, the trends observed in this subgroup were consistent with those in the main analysis, and the SGLT2 inhibitor group showed significant reductions in HbA1c, BMI, body weight, MACE, UTI, graft rejection, and all‐cause mortality compared with the control group (Table 2). This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.